Aligos Therapeutics, Inc.
ALGS
$5.60
-$0.16-2.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 93.47% | -15.89% | 36.96% | -98.81% | -136.82% |
| Total Depreciation and Amortization | -26.30% | 34.63% | 16.82% | -15.06% | 33.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.18% | -779.52% | -94.61% | 755.42% | 98.62% |
| Change in Net Operating Assets | -1,544.44% | 164.50% | -257.57% | 64.73% | 124.25% |
| Cash from Operations | -7.88% | -6.36% | 10.68% | -57.02% | 25.85% |
| Capital Expenditure | 98.55% | 25.00% | 52.33% | -77.06% | -153.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -28.57% | 1,914.41% | -104.03% | 221.78% | 10.70% |
| Cash from Investing | -28.43% | 1,828.40% | -104.24% | 220.96% | 10.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 74.19% | -1,966.67% | 70.00% | -900.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 75.57% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 454.84% | -150.41% | 332.08% | 70.06% | -100.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.71% | 149.66% | -201.54% | 142.26% | -249.87% |